Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up
HemaSphere · 2026-10 · 10 (10)
DOI: 10.1002/hem3.70507 ↗Kurz gefasst
Leitlinie in der Zeitschrift HemaSphere, online erschienen am 19.10.2026. Verfasst von Marco Ladetto und 17 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina of Traslazionale Università del Piemonte Orientale Alessandria Italy. Die Arbeit nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Follicular lymphoma (FL) is the second most common lymphoma subtype in Europe, with a median age at diagnosis of 60–65 years. It is generally considered an indolent disease, and the median overall survival at diagnosis now likely exceeds 20 years. However, considerable heterogeneity exists. Diagnosis requires adequate biopsy material and a specialized hematopathologist. Staging and prognosis rely on positron emission tomography (PET)‐computed tomography (CT). Prognostication at diagnosis is based on several validated clinical prognostic scores. Localized disease is usually treated with radiotherapy ± Rituximab. The treatment of disseminated disease includes active surveillance (or in selected cases Rituximab monotherapy) for low‐tumor burden patients, and most often immunochemotherapy (or in selected cases chemo‐free therapeutic options), ±antibody maintenance in high‐tumor burden patients. For relapsed or refractory disease, treatment with Rituximab‐Lenalidomide combination ± Tafasitamab or Epcoritamab from the first relapse and single‐agent bispecific antibodies, chimeric antigen receptor T‐cell therapy (CAR‐T) cells, and Zanubrutinib‐Obinutuzumab after second relapse should be prioritized over immunochemotherapy. Given the long natural history and risk of relapse, careful follow‐up is an important part of patient management. Patients should be actively involved in decision‐making. In this guideline, we present current evidence‐based recommendations for diagnosis, staging, treatment, and follow‐up.
Autor:innen und Institutionen
- Dipartimento di Medicina of Traslazionale Università del Piemonte Orientale Alessandria Italy.
- IRCCS, Azienda Ospedaliero-Universitaria Santi Antonio e Biagio e Cesare Arrigo Alessandria Italy.
- Lymphoma Coalition Ontario Canada.
- ELLyE - Patient Organization Paris France.
- Department of Radiation Oncology University Hospital of Heidelberg Heidelberg Germany.
- Department of Pathology University Hospital Schleswig-Holstein Kiel Germany.
ORCID-Profile: Marco Ladetto, Klaus Herfarth, Wolfram Klapper, Sirpa Leppa, Stefano Luminari, Franck Morschhauser, Jessica Okosun, Ewa Paszkiewicz-Kozik, Marek Trneny, Judith Trotman, Umut Yilmaz
Zitieren
APA
Ladetto, M., Bolaños, N., Bouguet, G., Herfarth, K., Klapper, W., Leppa, S., Linton, K., Lopez-Guillermo, A., Luminari, S., Morschhauser, F., Okosun, J., Paszkiewicz-Kozik, E., Thieblemont, C., Tonino, S. H., Trneny, M., Trotman, J., Yilmaz, U., & Dreyling, M. (2026). Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70507
Vancouver
Ladetto M, Bolaños N, Bouguet G, Herfarth K, Klapper W, Leppa S, et al. Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up. HemaSphere. 2026;10(10). doi:10.1002/hem3.70507
BibTeX
@article{Ladetto2026,
author = {Ladetto, Marco and Bolaños, Natacha and Bouguet, Guy and Herfarth, Klaus and Klapper, Wolfram and Leppa, Sirpa and Linton, Kim and Lopez-Guillermo, Armando and Luminari, Stefano and Morschhauser, Franck and Okosun, Jessica and Paszkiewicz-Kozik, Ewa and Thieblemont, Catherine and Tonino, Sanne Helene and Trneny, Marek and Trotman, Judith and Yilmaz, Umut and Dreyling, Martin},
title = {Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {10},
doi = {10.1002/hem3.70507}
}
EUVIMED